Sweeg on vaccines....Re: Corrected Adjuvant Corixa Patent (6,800,613)
sweegan...@yahoo.com
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
len...@courant.com, michae...@po.state.ct.us,
con...@po.state.ct.us, executiv...@nytimes.com, managing-
edi...@nytimes.com, news...@nytimes.com, the-...@nytimes.com,
biz...@nytimes.com, for...@nytimes.com, me...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, ubi...@courant.com, ma...@concentric.net,
camp...@courant.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, hor...@courant.com,
commissi...@po.state.ct.us, cohen...@aol.com,
FalN...@aol.com, brans...@comcast.net, vts...@comcast.net,
o...@po.state.ct.us, da...@davila-dilzer.com,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, hor...@courant.com,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, thomas...@usdoj.gov, amcg...@rms-law.com,
rjmu...@aol.com, paulcrai...@yahoo.com,
sidney_b...@yahoo.com, criminal...@usdoj.gov,
karla.d...@usdoj.gov, christophe...@usdoj.gov
Subject: Sweeg on vaccines....Re: Corrected Adjuvant Corixa Patent
(6,800,613)
Date: Feb 9, 2008 2:32 AM
Sweeganheimer continues his fairy-ass hysteria over MMR and autism,
when we have
learned two primary things about vaccines from the LYMErix fiasco:
1) Allen Steere never revealed to the FDA and the public that he had
identified
a genetic link to the hypersensitivity (allergy) aspect of OspA:
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=PureSearch&db=pubmed&term=steere%20AC%5BAuthor%5D%20AND%20HLA%5BAll%20Fields%5D
MEANING: the same screening should be applied for all children for all
vaccines
(this is not done because it is too expensive; the CDC says the
vaccines damage
is a "calculated risk.")
2) These idiots hardly have the vaccine carrier or adjuvant business
down yet, if
they, Corixa, wanted to start a whole new business selling vaccine
adjuvants based
on a modified OspA- because they found OspA to be too toxic.
If you look at the older published data on Rubella vaccines trials you
will find
them to be **** as sloppametric as the LYMErix trial.**** Many, many
cases of encephalitis
or delayed encephalitis have been identified in numerous ways. It has
even been
shown that measles encephalitis from vaccination (vaccine failure)
does not show
up until the teenage years ("schizophrenia" or the dementia from
encephalitis).
McSweegan actually never made any discoveries in his entire career,
but he seems
to be content with being a salesman for BigPharma. We at BigPharma
did not think
too much of the hack scientists who could not make it in science, and
who decided
to go into drug sales for the same company, if ya know what I mean.
Some people
are just not cut out for science, although they may be good in math
and somehow
used that ability to pass the college tests.
We sometimes see the same thing in engineering/design.
So don't listen to any BS from the likes of McSweegan. He is not a
real scientist.
http://www.actionlyme.org/McSweegan.htm
He's nothing more than a lying blowhard stalker.
Kathleen M. Dickson
-----Original Message-----
>From: Kathleen <janmu...@earthlink.net>
>Sent: Feb 6, 2008 12:09 PM
>Subject: Corrected Adjuvant Corixa Patent (6,800,613) Re: [SpinLyme] can anyone
(Kathleen) explain this?
>
>
>CORIXA ADJUVANT PATENT:
>
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,800,613.PN.&OS=PN/6,800,613&RS=PN/6,800,613
>
>
>Corrected
>
>
>-----Original Message-----
>>From: Kathleen <janmu...@earthlink.net>
>>Sent: Feb 6, 2008 10:30 AM
>>Subject: Re: [SpinLyme] can anyone (Kathleen) explain this?
>>
>>
>>They're simply creating recombinant vaccines with added immunostimulatory
properties.
>>
>>Like, for example, the crooks (Dave Persing, Corixa) found out native OspA
(LYMErix) was too stimulatory (toxic), so instead of telling everyone
it was a
>>toxin, they modified it and tried to sell the modified lipoprotein as an
"adjuvant."
http://www.actionlyme.org/EMBASSIES_CORIXA_TLR_13_JULY_06.htm
>>
>>What he is talking about there is modified OspA to be sold as a vaccine
adjuvant.
>>
>>You can see here that he admits the native proteins may be too toxic:
http://www.actionlyme.org/STEALTH_DISABLERS.htm
>>
>>1) "Accordingly, the methods of the invention provide a powerful
and selective approach for modulating the innate immune response
pathways in animals
without giving rise to the toxicities often associated with the native
bacterial
components that normally stimulate those pathways."
>>US Persing Patent 6800613
>>http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=3&f=G&l=50&co1=AND&d=PTXT&s1=tlr&s2=corixa&OS=tlr+AND+corixa&RS=tlr+AND+corixa
>>
>>
>>Here is the patent Karen Forschner of the Lyme Foundation presented to the
FDA that resulted in LYMErix being yanked:
http://www.actionlyme.org/KFORSCHNER_DISCOVERS_LYME_TOXIN.htm
>>"Borrelia burgdorferi polypeptides and uses thereof
>>
>>"Abstract
>>
>>"The present invention provides novel polypeptides which are substantially
free of a B. burgdorferi spirochete or fragments thereof and which are
thus useful
in compositions and methods for the treatment and prevention of B.
burgdorferi infection
and Lyme disease. In one preferred embodiment, this invention provides
modified
OspA polypeptides and pharmaceutically effective compositions and
methods comprising
those polypeptides. Preferred modified OspA polypeptides are
characterized by modifications
which diminish and/or ablate their ability to bind the human MHC
allele HLA-DRB1*0401."
>>
>>
>>SOMETHING THAT BINDS THE MHC COMPLEX IS KNOWN AS A TOXIN OR A SUPERANTIGEN.
>>
>>So, for some people, LYMErix was truly a poison and all the crooks knew
about it but said nothing.
>>
>>At the other end of the inate immune spectrum, you got immune suppression,
which Gary Wormser also published about.
>>
>>Not a one of them said a word about how dangerous they knew LYMErix was.
>>
>>
>>Kathleen
>>
>>
>>
>>
>>
>>-----Original Message-----
>>>From:
>>>Sent: Feb 6, 2008 9:28 AM
>>>To: Spin...@yahoogroups.com
>>>Subject: [SpinLyme] can anyone (Kathleen) explain this?
>>>
>>>
>>> Int J Med Microbiol. 2008 Jan 3;298(1-2):135-142. Epub 2007 Sep 20.
Links
>>> Development of hepatitis B virus capsids into a whole-chain protein
antigen
>>>display platform: New particulate Lyme disease vaccines.
>>> Nassal M, Skamel C, Vogel M, Kratz PA, Stehle T, Wallich R, Simon MM.
>>>
>>> Department of Internal Medicine II/Molecular Biology, University Hospital
>>>Freiburg, Hugstetter Straße 55, D-79106 Freiburg, Germany.
>>> The immunogenicity of peptides and small protein fragments can be
>>>considerably enhanced by their presentation on particulate carriers
such as capsid-like
>>>particles (CLPs) from hepatitis B virus (HBV). HBV CLPs are icosahedral
>>>nanoparticles formed by 90 or 120 core protein dimers. Insertions into
the
>>>immunodominant c/e1 B cell epitope, a surface-exposed loop on the HBV
capsid protein,
>>>are especially immunogenic. Here we investigated whether the HBV core
protein
>>>can be exploited as a vaccine carrier for whole-chain protein antigens,
using
>>>two clinically relevant proteins derived from a bacterial human pathogen,
the
>>>Lyme disease agent Borrelia burgdorferi. For this purpose we analyzed
CLP
>>>formation by core fusions with the entire 255-amino-acid ectodomain
of outer
>>>surface lipoprotein A (OspA), and with two distinct, 189 amino acid
long variants of
>>>the dimeric OspC (OspC(a), OspC(b)) of B. burgdorferi. OspA appropriately
>>>inserted into the HBV core protein yielded a multimerization-competent
fusion
>>>protein, termed coreOspA. Although only partially assembling into regular
CLPs,
>>>coreOspA induced antibodies to OspA, including the Ig isotype profile
and
>>>specificity for the protective epitope "LA-2", with an efficiency
similar to that
>>>of recombinant lipidated OspA, the first generation vaccine against
Lyme
>>>disease. Moreover, coreOspA actively and passively protected mice against
subsequent
>>>challenge with B. burgdorferi. Fusions with the two OspC variants were
found
>>>to efficiently form regular CLPs, most probably by OspC dimerization
across
>>>different core protein dimers. In mice, both coreOspC preparations induced
>>>high-titered antibody responses to the homologous but also to the heterologous
OspC
>>>variant, which conferred protection against challenge with B. burgdorferi.
>>>The data demonstrate the principal applicability of HBV CLPs to act
as potent
>>>immunomodulator even for structurally complex full-length polypeptide
chains,
>>>and thus open new avenues for novel vaccine designs.
>>> PMID: 17888729 [PubMed - as supplied by publisher]
>>>
>>>
>>>
>>>
>>>
>>>
>>>
>>>
>>>**************
>>>Biggest Grammy Award surprises of all time on AOL Music.
>>>
>>>(http://music.aol.com/grammys/pictures/never-won-a-grammy?NCID=aolcmp003000000025
>>>48)
>>>
>>>
>>>[Non-text portions of this message have been removed]
>>>
>>>
>>>
>>>
>>>Yahoo! Groups Links
>>>
>>>
>>>
>>
>>
>>
>>
>>Yahoo! Groups Links
>>
>>
>>
>
>
cowabu...@yahoo.com
SCROLL ON BY
Mo
> To: SpinL...@yahoogroups.com, kshep...@calea.org, fitz...@gmail.com,
> patrick.fitzger...@usdoj.gov, modelt1...@sbcglobal.net,
> jdra...@nejm.org, lett...@courant.com, Jgerberd...@cdc.gov,
> len...@courant.com, michael.c...@po.state.ct.us,
> conn...@po.state.ct.us, executive-edi...@nytimes.com, managing-
> edi...@nytimes.com, news-t...@nytimes.com, the-a...@nytimes.com,
> biz...@nytimes.com, fore...@nytimes.com, me...@nytimes.com,
> natio...@nytimes.com, dv...@cdc.gov, brigidcalla...@optonline.net,
> t...@hotmail.com, ubi...@courant.com, m...@concentric.net,
> campb...@courant.com, jhornber...@fff.org, thomas.car...@usdoj.gov,
> thomas.r...@po.state.ct.us, kur...@washpost.com,
> georgew...@washpost.com, hor...@courant.com,
> commissioner....@po.state.ct.us, cohencol...@aol.com,
> FalNie...@aol.com, bransfi...@comcast.net, vtsh...@comcast.net,
> o...@po.state.ct.us, d...@davila-dilzer.com,
> scott.mur...@po.state.ct.us, governor.r...@po.state.ct.us,
> attorney.gene...@po.state.ct.us, randall.samb...@usdoj.gov
> Cc: fran...@ucia.gov, dr-ahmadine...@president.ir,
> eugenerobin...@washpost.com, hor...@courant.com,
> bmil...@newstimes.com, t...@hotmail.com, rastr...@aol.com,
> billcurr...@gmail.com, thomas.car...@usdoj.gov, amcgui...@rms-law.com,
> rjmur...@aol.com, paulcraigrobe...@yahoo.com,
> sidney_blument...@yahoo.com, criminal.divis...@usdoj.gov,
> karla.dobin...@usdoj.gov, christopher.chris...@usdoj.gov
>
> Subject: Sweeg on vaccines....Re: Corrected Adjuvant Corixa Patent
> (6,800,613)
>
> Date: Feb 9, 2008 2:32 AM
>
> http://id50.blogspot.com/
>
> Sweeganheimer continues his fairy-ass hysteria over MMR and autism,
> when we have
> learned two primary things about vaccines from the LYMErix fiasco:
>
> 1) Allen Steere never revealed to the FDA and the public that he had
> identified
> MEANING: the same screening should be applied for all children for all
> vaccines
> (this is not done because it is too expensive; the CDC says the
> vaccines damage
> is a "calculated risk.")
>
> 2) These idiots hardly have the vaccine carrier or adjuvant business
> down yet, if
> they, Corixa, wanted to start a whole new business selling vaccine
> adjuvants based
> on a modified OspA- because they found OspA to be too toxic.
>
> If you look at the older published data on Rubella vaccines trials you
> will find
> them to be **** as sloppametric as the LYMErix trial.**** Many, many
> cases of encephalitis
> or delayed encephalitis have been identified in numerous ways. It has
> even been
> shown that measles encephalitis from vaccination (vaccine failure)
> does not show
> up until the teenage years ("schizophrenia" or the dementia from
> encephalitis).
>
> but he seems
> to be content with being a salesman for BigPharma. We at BigPharma
> did not think
> too much of the hack scientists who could not make it in science, and
> who decided
> to go into drug sales for the same company, if ya know what I mean.
> Some people
> are just not cut out for science, although they may be good in math
> and somehow
> used that ability to pass the college tests.
>
> We sometimes see the same thing in engineering/design.
>
> real scientist.http://www.actionlyme.org/McSweegan.htm
>
> He's nothing more than a lying blowhard stalker.
>
> Kathleen M. Dickson
>
> -----Original Message-----
> >From: Kathleen <janmusin...@earthlink.net>
> >Sent: Feb 6, 2008 12:09 PM
> >Subject: Corrected Adjuvant Corixa Patent (6,800,613) Re: [SpinLyme] can anyone
>
> (Kathleen) explain this?
>
> >CORIXA ADJUVANT PATENT:
>
>
>
>
> >Corrected
>
> >-----Original Message-----
> >>From: Kathleen <janmusin...@earthlink.net>
> >>Sent: Feb 6, 2008 10:30 AM
> >>Subject: Re: [SpinLyme] can anyone (Kathleen) explain this?
>
> >>They're simply creating recombinant vaccines with added immunostimulatory
> properties.
>
> >>Like, for example, the crooks (Dave Persing, Corixa) found out native OspA
>
> (LYMErix) was too stimulatory (toxic), so instead of telling everyone
> it was a>>toxin, they modified it and tried to sell the modified lipoprotein as an
>
> "adjuvant."http://www.actionlyme.org/EMBASSIES_CORIXA_TLR_13_JULY_06.htm
>
> >>What he is talking about there is modified OspA to be sold as a vaccine
> adjuvant.
>
> >>You can see here that he admits the native proteins may be too toxic:
>
> http://www.actionlyme.org/STEALTH_DISABLERS.htm
>
> >>1) "Accordingly, the methods of the invention provide a powerful
>
> and selective approach for modulating the innate immune response
> pathways in animals
> without giving rise to the toxicities often associated with the native
> bacterial
> components that normally stimulate those pathways.">>US Persing Patent 6800613
cowabu...@yahoo.com
Mo
> (6,800,613)
>
> Date: Feb 9, 2008 2:32 AM
>
> http://id50.blogspot.com/
>
> Sweeganheimer continues his fairy-ass hysteria over MMR and autism,
> when we have
> learned two primary things about vaccines from the LYMErix fiasco:
>
> 1) Allen Steere never revealed to the FDA and the public that he had
> identified
>
> He's nothing more than a lying blowhard stalker.
>
> Kathleen M. Dickson
>
> -----Original Message-----
> >From: Kathleen <janmusin...@earthlink.net>
> >Sent: Feb 6, 2008 12:09 PM
> >Subject: Corrected Adjuvant Corixa Patent (6,800,613) Re: [SpinLyme] can anyone
>
> (Kathleen) explain this?
>
> >CORIXA ADJUVANT PATENT:
>
>
>
>
> >Corrected
>
> >-----Original Message-----
> >>From: Kathleen <janmusin...@earthlink.net>
> >>Sent: Feb 6, 2008 10:30 AM
> >>Subject: Re: [SpinLyme] can anyone (Kathleen) explain this?
>
> >>They're simply creating recombinant vaccines with added immunostimulatory
> properties.
>
> >>Like, for example, the crooks (Dave Persing, Corixa) found out native OspA
>
> (LYMErix) was too stimulatory (toxic), so instead of telling everyone
> it was a>>toxin, they modified it and tried to sell the modified lipoprotein as an
>
> "adjuvant."http://www.actionlyme.org/EMBASSIES_CORIXA_TLR_13_JULY_06.htm
>
> >>What he is talking about there is modified OspA to be sold as a vaccine
> adjuvant.
>
> >>You can see here that he admits the native proteins may be too toxic:
>
> http://www.actionlyme.org/STEALTH_DISABLERS.htm
>
> >>1) "Accordingly, the methods of the invention provide a powerful
>
> and selective approach for modulating the innate immune response
> pathways in animals
> without giving rise to the toxicities often associated with the native
> bacterial
> components that normally stimulate those pathways.">>US Persing Patent 6800613